Doç. Dr.Burak Civelek

  • İlgi Alanları
  • Meme kanseri
  • Kolon kanseri
  • Mide kanseri
  • Akciğer kanseri
  • Prostat kanseri

Eğitim ve Uzmanlık
1996 – Gazi Tıp fakültesi – Tıp eğitimi
2009 – Ankara Numune Hastanesi: dahiliye uzmanlığı
2012– Ankara Numune Hastanesi:: Tıbbi Onkoloji Uzmanlığı

Deneyim
2003 - 2008 - Ankara Numune Hastanesi daihiliye kliniği
2009-2012: Ankara Numune hastanesi tıbbi onkoloji kliniği
2012-2014: Kırıkkale üniversitesi tıp fakültesi tıbbi onkoloji kliniği
2014-2016: acıbadem kayseri hastanesi
2016-2016: Elazığ Medical park hastanesi
2016:2020: Acıbadem Kayseri hastanesi
2020-2021: A life hospştal
2021: vm medicalpark ankara hastanesi

Mesleki Üyelikler
Türk Tıbbi Onkoloji Derneği

Uluslararası hakemli dergilerde yayımlanan makaleler

  1. Kos FT, Sendur MA, Aksoy S, Sezer S, Civelek B, Yazici O, Yaman S, Eren T, Zengin N. “Evaluation of the Renal Function Using Cystatin C Level in the Patients Receiving Cisplatin-Based Chemotherapy.” Ren Fail 2013;35(5):705-10. doi: 10.3109/0886022X.2013.777929. Epub 2013 Mar 27.
  2. F T. Kos*, B. Civelek, M M. Seker, Z. Arik, S. Aksoy, D. Uncu, N. Ozdemir, N. Zengin “Is There an Association between Blood Group and Survival in Pancreatic Cancer?” Asian Pac J Cancer Prev. 2012;13(12):6151-3.
  3. Nahit Sendur MA, Aksoy S, Civelek B, Zengin N. “Imatinib-induced anasarca without heart failure: capillary leakage?”J BUON 2012 Jan-Mar;17(1):188-9.
  4. Kos FT, Uncu D, Oksuzoglu B, Aksoy S, Ozdemir N, Odabas H, Isik M, Civelek B, Zengin N. “Long term survival in a metastatic alveolar soft part sarcoma at the time of diagnosis: a case with 17 years of follow-up.” J BUON. 2011 Apr-Jun;16(2):376-7
  5. Odabas H, Ozdemir N, Isik M, Abali H, Oksuzoglu B, Kos T, Civelek B, Babacan AN, Dogan U, Zengin N. “Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment” J BUON. 2011 Jul-Sep;16(3):460-3.
  6. Isik M, Caner S, Metin Seker M, Civelek B, Odabas H, Ozdemir N, Uncu D, Zengin N. “Gastric adenocarcinoma under the age of 40; more metastatic, less differentiated” J BUON. 2011 Apr-Jun;16(2):253-6.
  7. Seker, M.M., S. Aksoy, N.Y. Ozdemir, D. Uncu, B. Civelek, M.B. Akıncı, N. Zengin, “Succesful treatment of chronic hiccup with baclofen in cancer”, Med Oncol, doi: 10.1007/s12032-011-9910-3, 2011
  8. Civelek B, Aksoy S, Kös T, Seker MM, Arik Z, Sendur MA, Yaman S, Cihan S, Ozdemir NY, Uncu D, Kulaçoglu S, Zengin N. “Isolated testicular Metastasis of Gastric Cancer” J Gastrointest Cancer. 2011 Jul 15. 43(1)  P:64-66 doi10.1007/s12029-011-9305-x
  9. Kos FT, Yazici O, Civelek B, Seker M, Arik Z, Aksoy S, Uncu D, Ozdemir N, Zengin N. “Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale” Wien Klin Wochenschr. 2014 Jan;126(1-2):36-41 doi: 10.1007/s00508-013-0453-9
  10. Kos T, Aksoy S, Sendur MA, Arik Z, Civelek B, Kandemir N, Ozdemir NY, Zengin N, Altundag K “Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes” J BUON. 2013 Jul-Sep;18(3):608-13.
  11. Odabas H, Ozdemir NY, Ziraman I, Aksoy S, Abali H, Oksuzoglu B, Isik M, Civelek B, Dede D, Zengin N. “Effect of port-care frequency on venous port catheter-related complications in cancer patients” Int J Clin Oncol. 2014 Aug;19(4):761-6 doi:10.1007/s10147-013-0609-7
  12. Bulent Akinci M, Algin E, Inal A, Odabas H, Berk V, Coskun U, Uyeturk U, Isikdogan A, Aksoy S, Civelek B, Sevinc A, Buyukberber S. “Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study” J BUON. 2013 Apr-Jun;18(2):314-20.
  13. Kos FT, Sendur MA, Aksoy S, Celik HT, Sezer S, Civelek B, Yaman S, Zengin N. “Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy” Asian Pac J Cancer Prev. 2013;14(2):1111-4.
  14. Sendur MA, Aksoy S, Yaman S, Arik Z, Tugba Kos F, Akinci MB, Civelek B, Yildirim Ozdemir N, Uncu D, Zengin N “Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity” J BUON. 2013 Jan-Mar;18(1):274-80.
  15. Ozdemir N, Abali H, Vural M, Yalcin S, Oksuzoglu B, Civelek B, Oguz D, Bostanci B, Yalcin B, Zengin N. “Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study”. Cancer Chemother Pharmacol. 2014 Dec;74(6):1139-47 doi:10.1007/s00280-014-2586-6
  16. Civelek B. Aksoy S, Sendur MA, Yazıcı O, Kanmaz H, Kos FT, Yıldırım N, Uncu D, Zengin N. “Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma” J BUON 2014 Dec 19(4):906-912
  17. Civelek B, Aksoy S, Kos T, Arık Z, Akıncı MB, Uncu D, Özdemir N, Cihan S, Zengin N. “Duodenal adenocarcinoma: A rare cause of chyloperitoneum (chylous ascites)” Indian J Cancer. 2015 Jan-Mar;52(1):109. doi: 10.4103/0019-509X.175565.
  18. Urvay S, Eren T, Civelek B, Kilickap S, Yetiysigit T, Ozaslan E. “The role of primary tumor resection in patients with stage IV colorectal cancer with unresectable metastases” J BUON. Mar-Apr 2020;25(2):939-944.
  19. Urvay S, Civelek B, Özaslan E, Sürel AA “Chemotherapy at the End of Life” Palliat Care 2021 Apr;36(2):73-77. doi:10.1177/0825859720946505

Urvay S, Demir H, Gokyer A, Hacıbekiroğlu İ, Küçükarda A, Çakır E, Beypınar I, Demir N, Civelek B, Özaslan E, Investigation of the Effect of Tumor Location in Patients with Stage III Colon Cancer Receiving Adjuvant Oxaliplatine-Based Adjuvant Chemotherapy UHOD Number: 1 Volume: 31 Year: 2021 doi: 10.4999/uhod.214409